Experience with second-line trabectedin in daily clinical practice: case studies.

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced soft tissue sarcoma requires effective second-line treatment options.
• Trabectedin is a recommended second-line therapy for advanced soft tissue sarcoma.
• Balancing tumor control with quality of life is crucial for these patients.

Purpose of the Study:

• To illustrate long-lasting patient responses to second-line trabectedin therapy.
• To highlight the efficacy and tolerability of trabectedin in diverse soft tissue sarcoma cases.

Main Methods:

• Presentation of three distinct case studies of patients with advanced soft tissue sarcoma.
• Treatment involved second-line trabectedin, with varying cycle counts and durations.
• Patient outcomes, including disease control, quality of life, and adverse events, were monitored.

Main Results:

• A patient with metastatic leiomyosarcoma achieved 2 years of disease control with excellent tolerability.
• A patient with metastatic solitary fibrous tumor remained asymptomatic after 30 cycles, with ongoing treatment.
• A young patient with liposarcoma maintained an active lifestyle for over 2 years during treatment.

Conclusions:

• Second-line trabectedin can lead to durable tumor control in advanced soft tissue sarcoma.
• Trabectedin demonstrates a favorable safety profile and preserves quality of life.
• These cases support trabectedin's role in managing advanced soft tissue sarcomas.